The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t (9;11) (p22;q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified; BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.

Target	MLLT3
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Tested Applications	WB
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Immunogen	KLH-conjugated synthetic peptide between 39-65 amino acids from the N-terminal region of human MLLT3.
Purification	Purified Rabbit Polyclonal Antibody.
Isotype	IgG
Conjugation	Unconjugated
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Swiss Prot	P42568
Buffer	PBS containing 0.09% sodium azide.
UNSPSC Code	12352203
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.